Area of research
Molecular Biology · Pharmacology
Research interest
Research focused on Demethylase and Lactate dehydrogenase, with related work in Histone, Deubiquitinating enzyme, Thioredoxin reductase. Notable publications include 'Gene expression analysis identifies global gene dosage sensitivity in cancer', 'A selective USP1–UAF1 inhibitor links deubiquitination to DNA damage responses', and 'KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance'.
A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2
Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy
Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance
Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy
KDM5 histone demethylases repress immune response via suppression of STING
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A
Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)
Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds
A high-throughput small molecule screen identifies synergism between DNA methylation and Aurora kinase pathways for X reactivation
Gene expression analysis identifies global gene dosage sensitivity in cancer
High-throughput screening for modulators of cellular contractile force
A selective USP1–UAF1 inhibitor links deubiquitination to DNA damage responses
4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-<i>N</i>-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a Potent Inhibitor of Bacterial Phosphopantetheinyl Transferase That Attenuates Secondary Metabolism and Thwarts Bacterial Growth
Discovery of a Novel Dual Fungal CYP51/Human 5-Lipoxygenase Inhibitor: Implications for Anti-Fungal Therapy
Evaluation of flap endonuclease-1 (FEN1) as a prognostic, predictive, and therapeutic target in breast (BC) and ovarian cancer (OVC).